Friday, June 20, 2025 6/20/2025

18F-FLUOROESTRADIOL PET/CT GUIDED FULVESTRANT THERAPY FOR PATIENTS WITH RECURRENT

Award Number: R21CA139814
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2009
PERIOD OF PERFORMANCE END DATE: 01/31/2013

Group Awards By:

View Award Description

18F-FLUOROESTRADIOL PET/CT GUIDED FULVESTRANT THERAPY FOR PATIENTS WITH RECURRENT - DESCRIPTION (provided by applicant): Endocrine therapy remains the backbone of systemic therapy in both early and advanced stage hormone receptor positive breast cancer. Metastatic breast cancer is not curable however, and virtually all patients will eventually develop resistance to both tamoxifen and the aromatase inhibitors. Fulvestrant is a new pure estrogen receptor antagonist which binds with high affinity to the estrogen receptor and inhibits receptor dimerization, which leads to downregulation of cellular estrogen and progesterone receptor levels. In a recent multicenter study of fulvestrant, the clinical benefit rate to fulvestrant and exemestane in their target population was 32%, indicating the need to individualize therapy to identify patients who might benefit from this treatment. Currently, there are no predictors to identify the two thirds of non-responders in the target population of patients who are prescribed fulvestrant following prior hormonal agents. [18F]Fluoroestradiol ([18F]FES) is an imaging agent which allows the non-invasive assessment of estrogen receptor (ER) expression in breast cancers, allowing quantitative assessment of radiolabeled estrogen uptake at tumor sites and the ability to assess receptor expression heterogeneity across metastatic sites. The main purpose of this study is to prospectively assess the potential of [18F]FES PET/CT imaging to predict the benefit of administering fulvestrant in women with recurrent or metastastic breast cancer who have progressed following treatment with aromatase inhibitors and/or tamoxifen. The study hypotheses are: 1) High [18F]FES uptake at the baseline scan in known tumor sites is predictive of clinical benefit to fulvestrant therapy, while low [18F]FES uptake in some or all active tumor sites is predictive of fulvestrant therapy failure 2) Limited blockage/downregulation of [18F]FES uptake after 3 months of fulvestrant therapy is predictive of treatment failure. To assess these hypotheses we will conduct a prospective phase II cohort study to determine whether [18F]FES uptake at baseline and/or after reaching pharmacological steady-state of fulvestrant therapy can predict clinical benefit to this drug. The accrual plan is 100 patients over 2 years. PUBLIC HEALTH RELEVANCE: Fulvestrant is a relatively new drug that can be used to treat patients with advanced breast cancer once they have become resistant to other forms of therapy. Since only around 30% of patients will benefit from fulvestrant therapy, we propose to determine whether a state- of-the art imaging technique can predict which patients will respond. Success would benefit breast cancer patients by allowing physicians to make better decisions about who should be treated with fulvestrant, and who may respond better to alternative treatments.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $0 )
2012	2010	BRITISH COLUMBIA CANCER AGENCY	660 WEST 10TH AVENUE	VANCOUVER		00000			Cancer Detection and Diagnosis Research	000	2	2/2/2012	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2010 ( Subtotal = $236,417 )
2010	2010	BRITISH COLUMBIA CANCER AGENCY	600 West 10th Avenue	VANCOUVER				CAN	Cancer Detection and Diagnosis Research	000	2	3/18/2010	NON-COMPETING CONTINUATION	$236,417
														Subtotal = $236,417

Issue Date FY: 2009 ( Subtotal = $236,417 )
2009	2009	BRITISH COLUMBIA CANCER AGENCY	600 West 10th Avenue	VANCOUVER				CAN	Cancer Detection and Diagnosis Research	001	1	3/23/2009	NEW	$21,492
2009	2009	BRITISH COLUMBIA CANCER AGENCY	600 West 10th Avenue	VANCOUVER				CAN	Cancer Detection and Diagnosis Research	000	1	3/16/2009	NEW	$214,925
														Subtotal = $236,417

Grand Total All Awards = $472,834

Top

All Categories

About

Search

Reports

Data Submission

Award Information

18F-FLUOROESTRADIOL PET/CT GUIDED FULVESTRANT THERAPY FOR PATIENTS WITH RECURRENT

Award Number: R21CA139814

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2009

PERIOD OF PERFORMANCE END DATE: 01/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer